Clinical Pharmacokinetics

, Volume 27, Issue 1, pp 1–5 | Cite as

Inhibition of Terfenadine Metabolism

Pharmacokinetic and Pharmacodynamic Consequences
  • Kari T. Kivistö
  • Pertti J. Neuvonen
  • Ulrich Klotz
Leading Article

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies [editorial]. JAMA 1993; 269: 1550–2PubMedCrossRefGoogle Scholar
  2. 2.
    Davies AJ, Harindra V, McEwan A, et al. Cardiotoxic effect with convulsions in terfenadine overdose [letter]. BMJ 1989; 298: 325PubMedCrossRefGoogle Scholar
  3. 3.
    Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90PubMedCrossRefGoogle Scholar
  4. 4.
    MacConnell TJ, Stanners AJ. Torsades de pointes complicating treatment with terfenadine [letter]. BMJ 1991; 302: 1469PubMedCrossRefGoogle Scholar
  5. 5.
    Zimmermann M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13: 1002–3PubMedGoogle Scholar
  6. 6.
    Mathews DR, McNutt B, Okerholm R, et al. Torsades de pointes occurring in association with terfenadine use [letter]. JAMA 1991; 266: 2375–6PubMedCrossRefGoogle Scholar
  7. 7.
    Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6PubMedCrossRefGoogle Scholar
  8. 8.
    Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole [abstract]. Clin Pharmacol Ther 1991; 49: 130Google Scholar
  9. 9.
    Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8PubMedCrossRefGoogle Scholar
  10. 10.
    Pohjola-Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45: 191–3PubMedCrossRefGoogle Scholar
  11. 11.
    Crane JK, Shih H-T. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993; 95: 445–6PubMedCrossRefGoogle Scholar
  12. 12.
    Honig PK, Wortham DC, Zamani K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53: 630–6PubMedCrossRefGoogle Scholar
  13. 13.
    Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014–8PubMedCrossRefGoogle Scholar
  14. 14.
    Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231–8PubMedCrossRefGoogle Scholar
  15. 15.
    Honig P, Wortham D, Zamani K, et al. Effect of erythromycin, clarithromycin and azithromycin on the pharmacokinetics of terfenadine [abstract]. Clin Pharmacol Ther 1993; 53: 161CrossRefGoogle Scholar
  16. 16.
    Cantilena L, Wortham D, Zamani K, et al. Effect of cimetidine and ranitidine on the pharmacokinetics and ECG pharmacodynamics of terfenadine [abstract]. Clin Pharmacol Ther 1993; 53: 161Google Scholar
  17. 17.
    Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989; 28: 166–70PubMedCrossRefGoogle Scholar
  18. 18.
    Seyffer R, Eichelbaum M, Jensen JC, et al. Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol 1989; 37: 231–3PubMedCrossRefGoogle Scholar
  19. 19.
    Back DJ, Tjia JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatol 1992; 126 Suppl. 39: 14–8PubMedCrossRefGoogle Scholar
  20. 20.
    Yun C, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21: 403–9PubMedGoogle Scholar
  21. 21.
    Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346–52PubMedCrossRefGoogle Scholar
  22. 22.
    Algra A, Tijssen JGP, Roelandt JRTC, et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83: 1888–94PubMedCrossRefGoogle Scholar
  23. 23.
    Kemp JP. Decreased antihistamine metabolism [letter]. Ann Allergy 1992; 69: 533PubMedGoogle Scholar
  24. 24.
    Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82PubMedCrossRefGoogle Scholar
  25. 25.
    Henahan S. Implications of terfenadine’s interactions. Reactions 1993; 449: 3–4CrossRefGoogle Scholar
  26. 26.
    Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990; 11: 2275–9PubMedCrossRefGoogle Scholar
  27. 27.
    Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268–9PubMedCrossRefGoogle Scholar
  28. 28.
    Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26: 91–8PubMedCrossRefGoogle Scholar
  29. 29.
    Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Kari T. Kivistö
    • 1
  • Pertti J. Neuvonen
    • 2
  • Ulrich Klotz
    • 1
  1. 1.Dr Margarete Fischer-Bosch-Institute of Clinical PharmacologyStuttgartGermany
  2. 2.Department of Clinical PharmacologyUniversity of HelsinkiHelsinkiFinland

Personalised recommendations